233 related articles for article (PubMed ID: 22678902)
1. Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching.
Feng D; Yang L; Bi X; Stone RC; Patel P; Barnes BJ
Eur J Immunol; 2012 Jun; 42(6):1477-87. PubMed ID: 22678902
[TBL] [Abstract][Full Text] [Related]
2. Monocytes from Irf5-/- mice have an intrinsic defect in their response to pristane-induced lupus.
Yang L; Feng D; Bi X; Stone RC; Barnes BJ
J Immunol; 2012 Oct; 189(7):3741-50. PubMed ID: 22933628
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic IFN-dependent and -independent effects of IRF5 on the pathogenesis of experimental lupus.
Xu Y; Lee PY; Li Y; Liu C; Zhuang H; Han S; Nacionales DC; Weinstein J; Mathews CE; Moldawer LL; Li SW; Satoh M; Yang LJ; Reeves WH
J Immunol; 2012 Apr; 188(8):4113-21. PubMed ID: 22422888
[TBL] [Abstract][Full Text] [Related]
4. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus.
Savitsky DA; Yanai H; Tamura T; Taniguchi T; Honda K
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10154-9. PubMed ID: 20479222
[TBL] [Abstract][Full Text] [Related]
5. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.
Richez C; Yasuda K; Bonegio RG; Watkins AA; Aprahamian T; Busto P; Richards RJ; Liu CL; Cheung R; Utz PJ; Marshak-Rothstein A; Rifkin IR
J Immunol; 2010 Jan; 184(2):796-806. PubMed ID: 20007534
[TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus.
Cham CM; Ko K; Niewold TB
Clin Dev Immunol; 2012; 2012():780436. PubMed ID: 23251221
[TBL] [Abstract][Full Text] [Related]
7. Potential T Cell-Intrinsic Regulatory Roles for IRF5 via Cytokine Modulation in T Helper Subset Differentiation and Function.
Brune Z; Rice MR; Barnes BJ
Front Immunol; 2020; 11():1143. PubMed ID: 32582209
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of IRF5 hyperactivation protects from lupus onset and severity.
Song S; De S; Nelson V; Chopra S; LaPan M; Kampta K; Sun S; He M; Thompson CD; Li D; Shih T; Tan N; Al-Abed Y; Capitle E; Aranow C; Mackay M; Clapp WL; Barnes BJ
J Clin Invest; 2020 Dec; 130(12):6700-6717. PubMed ID: 32897883
[TBL] [Abstract][Full Text] [Related]
9. IRF5 is elevated in childhood-onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors.
Shu J; Li L; Zhou LB; Qian J; Fan ZD; Zhuang LL; Wang LL; Jin R; Yu HG; Zhou GP
Oncotarget; 2017 Jul; 8(29):47184-47194. PubMed ID: 28525378
[TBL] [Abstract][Full Text] [Related]
10. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus.
Cherian TS; Kariuki SN; Franek BS; Buyon JP; Clancy RM; Niewold TB
Arthritis Rheum; 2012 Oct; 64(10):3383-7. PubMed ID: 22674082
[TBL] [Abstract][Full Text] [Related]
12. Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice.
Tada Y; Kondo S; Aoki S; Koarada S; Inoue H; Suematsu R; Ohta A; Mak TW; Nagasawa K
Arthritis Rheum; 2011 Mar; 63(3):738-48. PubMed ID: 21305501
[TBL] [Abstract][Full Text] [Related]
13. Lineage-Specific Functionality of an Interferon Regulatory Factor 5 Lupus Risk Haplotype: Lack of B Cell Intrinsic Effects.
Calise J; Marquez Renteria S; Gregersen PK; Diamond B
Front Immunol; 2018; 9():996. PubMed ID: 29867973
[TBL] [Abstract][Full Text] [Related]
14. Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis.
Matta B; Barnes BJ
Cytokine; 2020 Aug; 132():154731. PubMed ID: 31130331
[TBL] [Abstract][Full Text] [Related]
15. Lyn Kinase Suppresses the Transcriptional Activity of IRF5 in the TLR-MyD88 Pathway to Restrain the Development of Autoimmunity.
Ban T; Sato GR; Nishiyama A; Akiyama A; Takasuna M; Umehara M; Suzuki S; Ichino M; Matsunaga S; Kimura A; Kimura Y; Yanai H; Miyashita S; Kuromitsu J; Tsukahara K; Yoshimatsu K; Endo I; Yamamoto T; Hirano H; Ryo A; Taniguchi T; Tamura T
Immunity; 2016 Aug; 45(2):319-32. PubMed ID: 27521268
[TBL] [Abstract][Full Text] [Related]
16. Regulation and role of the transcription factor IRF5 in innate immune responses and systemic lupus erythematosus.
Ban T; Sato GR; Tamura T
Int Immunol; 2018 Oct; 30(11):529-536. PubMed ID: 29860420
[TBL] [Abstract][Full Text] [Related]
17. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.
Graham RR; Kozyrev SV; Baechler EC; Reddy MV; Plenge RM; Bauer JW; Ortmann WA; Koeuth T; González Escribano MF; ; Pons-Estel B; Petri M; Daly M; Gregersen PK; Martín J; Altshuler D; Behrens TW; Alarcón-Riquelme ME
Nat Genet; 2006 May; 38(5):550-5. PubMed ID: 16642019
[TBL] [Abstract][Full Text] [Related]
18. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.
Clynes R; Calvani N; Croker BP; Richards HB
Clin Exp Immunol; 2005 Aug; 141(2):230-7. PubMed ID: 15996187
[TBL] [Abstract][Full Text] [Related]
20. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease.
Ban T; Kikuchi M; Sato GR; Manabe A; Tagata N; Harita K; Nishiyama A; Nishimura K; Yoshimi R; Kirino Y; Yanai H; Matsumoto Y; Suzuki S; Hihara H; Ito M; Tsukahara K; Yoshimatsu K; Yamamoto T; Taniguchi T; Nakajima H; Ito S; Tamura T
Nat Commun; 2021 Jul; 12(1):4379. PubMed ID: 34282144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
